CS
PMVP icon

Credit Suisse’s PMV Pharmaceuticals PMVP Stock Holding History

Credit Suisse’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,122
Closed -$67.4K – 3236
2023
Q1 		$67.4K Buy
14,122
+5
+0% +$35 ﹤0.01% 3229
2022
Q4 		$123K Sell
14,117
-2,649
-16% -$28.2K ﹤0.01% 3296
2022
Q3 		$199K Buy
16,766
+6,226
+59% +$90K ﹤0.01% 3245
2022
Q2 		$150K Buy
+10,540
New +$153K ﹤0.01% 3428
2022
Q1 		– Sell
-8,942
Closed -$207K – 4163
2021
Q4 		$207K Buy
8,942
+206
+2% +$4.98K ﹤0.01% 4258
2021
Q3 		$260K Sell
8,736
-268
-3% -$8.56K ﹤0.01% 4137
2021
Q2 		$307K Buy
+9,004
New +$301K ﹤0.01% 4099
2021
Q1 		– Sell
-4,027
Closed -$248K – 4497
2020
Q4 		$248K Buy
+4,027
New +$158K ﹤0.01% 4041

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse's PMVP Position: Q2 2023 in Review

Credit Suisse sold out of PMV Pharmaceuticals (PMVP) in Q2 2023, closing a stake of 14,122 shares — an estimated $67.4K sold.

Credit Suisse first reported a position in PMVP in Q4 2020 and held it in 8 quarters. The position peaked at $307K in Q2 2021. 106 funds tracked by Wall St. Rank hold PMVP as of Q2 2023.

  • Credit Suisse reported no remaining PMV Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Credit Suisse sold 14,122 PMV Pharmaceuticals shares in Q2 2023, an estimated $67.4K.
  • Credit Suisse first reported a position in PMV Pharmaceuticals in Q4 2020 and held it in 8 quarters.
  • Credit Suisse's PMV Pharmaceuticals position peaked at $307K in Q2 2021.
  • 106 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.